NCT02994771 - A Phase I Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

February 3, 2019

Study Completion Date

April 5, 2022

Conditions

Secondary Lymphedema

Interventions

DRUG

Lymfactin® [1 x 10E10 vp]

Lymfactin® \[1 x 10E10 vp\] will be administered as a single dose via perinodal injection in a volume of 2 mL.

DRUG

Lymfactin® [1 x 10E11 vp]

Lymfactin® \[1 x 10E11 vp\] will be administered as a single dose via perinodal injection in a volume of 2 mL.

Trial Locations (3)

Toeoeloe Hospital, Department of Plastic Surgery, Helsinki

Tampere University Hospital, Department of Plastic Surgery, Tampere

Turku University Hospital, Department of Plastic Surgery, Turku